BIA
AVDL

Bell Investment Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

Bell Investment Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-62
Closed -$486 – 1891
2025
Q1 		$486 Hold
62
– – ﹤0.01% 1763
2024
Q4 		$652 Hold
62
– – ﹤0.01% 1699
2024
Q3 		$814 Buy
62
+31
+100% +$472 ﹤0.01% 1656
2024
Q2 		$436 Buy
+31
New +$505 ﹤0.01% 1859
2023
Q3 		– Sell
-33
Closed -$544 – 1930
2023
Q2 		$544 Buy
+33
New +$429 ﹤0.01% 1807

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bell Investment Advisors's AVDL Position: Q2 2025 in Review

Bell Investment Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q2 2025, closing a stake of 62 shares — an estimated $486 sold.

Bell Investment Advisors first reported a position in AVDL in Q2 2023 and held it in 5 quarters. The position peaked at $814 in Q3 2024. 173 funds tracked by Wall St. Rank hold AVDL as of Q2 2025.

  • Bell Investment Advisors reported no remaining Avadel Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Bell Investment Advisors sold 62 Avadel Pharmaceuticals shares in Q2 2025, an estimated $486.
  • Bell Investment Advisors first reported a position in Avadel Pharmaceuticals in Q2 2023 and held it in 5 quarters.
  • Bell Investment Advisors's Avadel Pharmaceuticals position peaked at $814 in Q3 2024.
  • 173 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2025.

Based on Bell Investment Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.